CN102526080A - Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof - Google Patents
Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof Download PDFInfo
- Publication number
- CN102526080A CN102526080A CN201110410629XA CN201110410629A CN102526080A CN 102526080 A CN102526080 A CN 102526080A CN 201110410629X A CN201110410629X A CN 201110410629XA CN 201110410629 A CN201110410629 A CN 201110410629A CN 102526080 A CN102526080 A CN 102526080A
- Authority
- CN
- China
- Prior art keywords
- lactoside
- weight portion
- methyl salicylate
- tablet
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicinal composition containing salicylic acid methyl ester lactoside. The medicinal composition comprises the following raw materials in parts by weight: 100 parts of salicylic acid methyl ester lactoside, 20-300 parts of a thinner, 1-8 parts of a disintegrating agent, 20-400 part of a bonding agent and 0.5-6 parts of a lubricating agent. The invention further discloses a salicylic acid methyl ester lactoside tablet, which consists of a tablet core and a film coating uniformly coated on the surface of the tablet core, wherein the tablet core consists of the medicinal composition containing the salicylic acid methyl ester lactoside; and the film coating comprises the following raw materials in parts by weight: 20-200 parts of a film forming material, 0-50 parts of a film forming aid and 600-2,000 parts of a solvent. The invention further discloses a preparation method of the tablet. The medicinal composition provided by the invention is convenient to take, and has low toxic and side effects; the dissolution rate of the tablet is high, and the stability is high; and the preparation methods are easy to operate, and the prepared products have stable and controllable quality.
Description
Technical field
The invention belongs to the Chinese drug preparation technique field, be specifically related to a kind of pharmaceutical composition that contains the methyl salicylate lactoside, tablet and preparation method thereof.
Background technology
NSAID (Nonsteroidal Antiinflammatory Drugs; NSAIDs) be one type of anti-inflammatory agent that does not contain the steroidal structure; NSAIDs is after aspirin synthesized in 1898 first; Existing over one hundred kind of thousands of brand listing over more than 100 year; This type medicine comprises aspirin, acetaminophen, indomethacin, naproxen, Nabumetone, diclofenac, ibuprofen, nimesulide, rofecoxib, celecoxib etc., and such medicine has antiinflammatory, rheumatism, pain relieving, bring down a fever and effect such as anticoagulation, is widely used in the alleviation of osteoarthritis, rheumatoid arthritis, multiple heating and various pain symptoms clinically.NSAIDs is that one of maximum drug kinds is used in the whole world at present, and the whole world has 3,000 ten thousand people using about every day.Though the NSAIDs chemical constitution is different, most NSAIDs has antiinflammation, and it suppresses leukocytic gathering through suppressing the synthetic of prostaglandin, reduces the formation of Kallidin I, suppresses effect performance antiinflammations such as hematoblastic coagulation.Symptom curative effect to control rheumatic and rheumatoid arthritis is affirmed.
Wherein as the aspirin of one of three big classical medicines on the medical history, from being widely used in antiinflammatory, the treatment of rheumatism analgesic 19th century so far clinically, but during as antiheumatic Drug therapy; Need the patient to take very heavy dose of (3-5g on the one, divides 4 times oral) ability onset, the gastrointestinal tract mucous zest to the patient is very big like this; Feeling sick, vomitting appears in the patient; Even ulcer, side effect such as hemorrhage, most of patients clothes median dose aspirin a couple of days, see that promptly FOB Fecal Occult Blood Testing is positive; Long-term patient taking this drug Peptic Ulcers is sent out the rate height.Except that the acidity of medicine directly caused the gastric mucosa damage, injecting drug use also can take place.Aspirin can see through gastric epithelial lipoprotein rete, destroys the protective effect of lipoprotein membrane, so gastric acid just permeates into damaging cells in the tissue reversiblely, it is damaged and hemorrhage to cause blood capillary.
Salicylic acid glucosides methyl compound is one type of new NSAID; The β glycosidase hydrolysis that its active component salicylic acid glucosides methyl is produced by flora at intestinal produces the bigcatkin willow methyl ester, in blood plasma and tissue; By the further hydrolysis of carboxy-lesterase, produce salicylic acid.The internal metabolism mode that it is unique is different from other NSAID, greatly reduces the gastrointestinal side effect of such medicine, and the length of holding time in vivo, can play a role for a long time.The methyl salicylate lactoside is exactly a kind of anti-inflammatory drug of wherein newly developing; But the pharmaceutical formulation or the preparation that also do not contain the methyl salicylate lactoside in the market; And because active component methyl salicylate lactoside is unformed powder; Mobile non-constant is difficult for being prepared into various regular dosage forms.
Summary of the invention
To the defective that exists in the prior art, an object of the present invention is to provide a kind of pharmaceutical composition that contains the methyl salicylate lactoside, this pharmaceutical composition taking convenience, toxic and side effects are little.
Another object of the present invention provides the methyl salicylate lactoside tablet of a kind of dissolution height, good stability.
A further object of the present invention provides the method for preparing of above-mentioned methyl salicylate lactoside tablet, and this method for preparing is simple, and prepared constant product quality is controlled.
For reaching above purpose; The technical scheme that the present invention adopts is: a kind of pharmaceutical composition that contains the methyl salicylate lactoside, this pharmaceutical composition comprises the raw material of following weight portion: 0.5～6 part of 100 parts of methyl salicylate lactosides, 20～300 parts of diluent, 1～8 part of disintegrating agent, 20～400 parts of binding agents and lubricant.
Further, said diluent is selected from one or more in starch, cyclodextrin, microcrystalline Cellulose and the lactose; Said disintegrating agent is carboxymethyl starch sodium, polyvinylpolypyrrolidone or the mixture of the two; Said binding agent is selected from starch slurry, polyvinylpyrrolidone K
30In alcoholic solution, dehydrated alcohol and the water one or more; Said lubricant is selected from one or more in magnesium stearate, Pulvis Talci and the stearic acid.
A kind of methyl salicylate lactoside tablet provided by the invention reaches the film-coat that evenly is coated on the sheet wicking surface by label and forms; Said label comprises the raw material of following weight portion: 0.5～6 part of 100 parts of methyl salicylate lactosides, 20～300 parts of diluent, 1～8 part of disintegrating agent, 20～400 parts of binding agents and lubricant; Said film-coat comprises the raw material of following weight portion: 20～200 parts of filmogens, 600～2000 parts of 0～50 part of coalescents and solvents.
Further, said diluent is selected from one or more in starch, cyclodextrin, microcrystalline Cellulose and the lactose; Said disintegrating agent is carboxymethyl starch sodium, polyvinylpolypyrrolidone or the mixture of the two; Said binding agent is selected from starch slurry, polyvinylpyrrolidone K
30In alcoholic solution, dehydrated alcohol and the water one or more; Said lubricant is selected from one or more in magnesium stearate, Pulvis Talci and the stearic acid.
Further, said filmogen is selected from one or more in hypromellose, ethyl cellulose, glyceryl triacetate, polyacrylic acid resin, the polyvinyl alcohol; Said coalescents is selected from one or more in titanium dioxide, Pulvis Talci or the Polyethylene Glycol, and said solvent is the solution that water and dehydrated alcohol mix with any ratio.
Further again, said filmogen comprises hypromellose 0～100 weight portion, ethyl cellulose 0～40 weight portion and glyceryl triacetate 0～40 weight portion; Said coalescents comprises titanium dioxide 0～10 weight portion, Pulvis Talci 0～20 weight portion and Polyethylene Glycol 0～20 weight portion; Said solvent is that concentration of volume percent is 70～95% alcoholic solution 700～1800 weight portions.
Further, said filmogen comprises hypromellose 1～100 weight portion, ethyl cellulose 0.5～20 weight portion and glyceryl triacetate 0.1～20 weight portion, and said coalescents is titanium dioxide 0～5 weight portion.
The method for preparing of above-mentioned methyl salicylate lactoside tablet provided by the invention comprises the steps:
(1) diluent and the disintegrating agent of said weight portion are crossed 10～100 mesh sieves, get the tablet inserts;
(2) the methyl salicylate lactoside of said weight portion is crossed 10～100 mesh sieves, get compound with the tablet inserts mix homogeneously of step (1);
(3) the binding agent wet granulation of the said weight portion of adding in compound; With 10～60 mesh sieve granulate, drying is 1～6 hour under 30～80 ℃ condition, and degree of drying is for controlling pellet moisture between 1～5%;
(4) lubricant of the said weight portion of adding in dried granulate, mix homogeneously is put the compacting label that gets in blocks on the tablet machine.
(5) filmogen, coalescents and the solvent with weight portion described in the film-coat is mixed with emulsion, stirs 30～90 minutes, obtains coating solution;
(6) under 30～70 ℃ condition, label being carried out coating, is standard to increase 1%～5% of label weight portion, obtains containing the tablet of methyl salicylate lactoside.
Further, in the step (3), baking temperature is 40～60 ℃, and be 2～4 hours drying time.
Further, in the step (4), in fluid bed or coating pan, label is carried out coating, the coating temperature is 40～60 ℃.
Of the present invention having the following advantages:
1, methyl salicylate lactoside pharmaceutical composition and the tablet of containing provided by the invention; Its active component methyl salicylate lactoside is in intestinal during metabolism; The β glycosidase hydrolysis that is at first produced by flora produces methyl salicylate, in blood plasma and tissue; By the further hydrolysis of carboxy-lesterase, produce salicylic acid.The internal metabolism mode of this uniqueness of methyl salicylate lactoside greatly reduces this medicine to the gastrointestinal side effect, and the length of holding time in vivo, can play a role for a long time.
2, because active component methyl salicylate lactoside is unformed powder; Mobile non-constant; Be 55 ° angle of repose, can not make tablet by direct compression, so the present invention mixes tabletting behind wet granulation with active component methyl salicylate lactoside with adjuvant; Improved the flowability of methyl salicylate lactoside greatly, be 34.9 ° angle of repose.
3, the material that uses among the present invention, it is convenient, cheap to originate, and the method for preparing of methyl salicylate lactoside tablet of the present invention is simple, and the constant product quality of being produced is controlled.
The specific embodiment
Below in conjunction with embodiment the present invention is done further description.
Reagent that uses among the embodiment and instrument and equipment all can be buied from market.
Embodiment 1
This embodiment is used to explain the method for preparing of methyl salicylate lactoside tablet provided by the invention.
Label is formed and consumption:
Film-coat is formed and consumption:
Filmogen:
Hypromellose 76g
Ethyl cellulose 1.6g
Glyceryl triacetate 1.6g
Coalescents:
Titanium dioxide 0.8g
Solvent:
Percent by volume is 70% alcoholic solution 600mL
Method for preparing: methyl salicylate lactoside, starch and the carboxymethyl starch sodium of above-mentioned consumption are crossed 60 mesh sieves, mix homogeneously; Put and add starch slurry (weight concentration 1%) granulation in the granulator; Vacuum drying is 3 hours under 50 ℃ of conditions; With particulate moisture Control between 1～2%; With the magnesium stearate that adds above-mentioned consumption behind the 14 mesh sieve granulate, tabletting makes the label (1000 of slices) that contains the methyl salicylate lactoside on tablet machine; It with 79.2g filmogen, 0.8g titanium dioxide and 600mL percent by volume 70% alcoholic solution mix homogeneously; Stirred 30 minutes; In coating pan, carry out coating under 30 ℃ as coating solution; Can prepare 1000 in methyl salicylate lactoside tablet, every contains active component methyl salicylate lactoside 50mg.
Embodiment 2:
This embodiment is used to explain the method for preparing of methyl salicylate lactoside tablet provided by the invention.
Label is formed and consumption:
Film-coat is formed and consumption:
Filmogen:
Hypromellose 47.5g
Ethyl cellulose 1g
Glyceryl triacetate 1g
Coalescents:
Titanium dioxide 0.5g
Solvent:
Percent by volume is 80% alcoholic solution 1000mL
Method for preparing: methyl salicylate lactoside, cyclodextrin and the polyvinylpolypyrrolidone of above-mentioned consumption are crossed 60 mesh sieves, mix homogeneously; Put and add polyvinylpyrrolidone K in the granulator
30Alcoholic solution (weight concentration 10%) is granulated, and 60 ℃ of vacuum dryings 3 hours between 1～2%, add the Pulvis Talci of above-mentioned consumption with particulate moisture Control behind the 20 mesh sieve granulate, and tabletting makes methyl salicylate lactoside sheet (1000 of slices) on tablet machine; It with 49.5g filmogen, 0.5g titanium dioxide and 1000mL percent by volume 80% alcoholic solution mix homogeneously; Stirred 60 minutes; In coating pan, carry out coating under 50 ℃ as coating solution; Can prepare 1000 in methyl salicylate lactoside tablet, every contains active component methyl salicylate lactoside 200mg.
Embodiment 3
This embodiment is used to explain the method for preparing of methyl salicylate lactoside tablet provided by the invention.
Label is formed and consumption:
Film-coat is formed and consumption:
Filmogen:
Hypromellose 58.2g
Ethyl cellulose 0.9g
Glyceryl triacetate 0.9g
Solvent:
Dehydrated alcohol 1000mL
Method for preparing: methyl salicylate lactoside, microcrystalline Cellulose and the polyvinylpolypyrrolidone of above-mentioned consumption are crossed 60 mesh sieves respectively; Abundant mix homogeneously; The water that adds 60mL is made binding agent, stirs and processes soft material, places wet granulator system wet granular; Put 75 ℃ vacuum drying oven inner drying; Between 1-2%, with the stearic acid and the dried granule mix homogeneously that add above-mentioned consumption behind the 30 mesh sieve granulate, tabletting makes methyl salicylate lactoside sheet (1000 of slices) on tablet machine with particulate moisture Control; With 60g filmogen and 1000mL dehydrated alcohol mix homogeneously, stirred 80 minutes, in coating pan, carry out coating under 55 ℃ as coating solution, can prepare 1000 in methyl salicylate lactoside tablet, every contains active component methyl salicylate lactoside 300mg.
Embodiment 4
This embodiment is used to explain the method for preparing of methyl salicylate lactoside tablet provided by the invention.
Label is formed and consumption:
Film-coat is formed and consumption:
Filmogen:
Polyvinyl alcohol 162g
Coalescents:
Titanium dioxide 1.8g
Pulvis Talci 1.8g
Polyethylene Glycol 15.0mL
Solvent:
Distilled water 1000mL
Method for preparing: methyl salicylate lactoside, microcrystalline Cellulose and the carboxymethyl starch sodium of above-mentioned consumption are crossed 60 mesh sieves respectively; Abundant mix homogeneously; Place wet granulator; Add 150g starch slurry (weight concentration 10%) and make binding agent system wet granular, put 55 ℃ vacuum drying oven inner drying, with particulate moisture Control between 1～2%; With the magnesium stearate and the dried granule mix homogeneously that add above-mentioned consumption behind the 40 mesh sieve granulate, tabletting makes methyl salicylate lactoside sheet (1000 of slices) on tablet machine; With 162g polyvinyl alcohol, 1.8g titanium dioxide, 1.8g Pulvis Talci, 15mL Polyethylene Glycol and 1000mL distilled water mix homogeneously; Stirred 90 minutes; In fluid bed, carry out coating under 65 ℃ as coating solution; Can prepare 1000 in methyl salicylate lactoside tablet, every contains active component methyl salicylate lactoside 400mg.
Embodiment 5
This embodiment is used to explain the method for preparing of methyl salicylate lactoside tablet provided by the invention.
Label is formed and consumption:
Film-coat is formed and consumption:
Filmogen:
Hypromellose 147g
Glyceryl triacetate 1.5g
Coalescents:
Titanium dioxide 1.5g
Solvent:
Distilled water 2000mL
Method for preparing: methyl salicylate lactoside, lactose and the carboxymethyl starch sodium of above-mentioned consumption are crossed 60 mesh sieves; Mix homogeneously; Place wet granulator to add 160mL dehydrated alcohol system wet granular, put 30 ℃ vacuum drying oven inner drying, with particulate moisture Control between 1～2%; With the magnesium stearate and the dried granule mix homogeneously that add above-mentioned consumption behind the 50 mesh sieve granulate, tabletting makes methyl salicylate lactoside sheet (1000 of slices) on tablet machine; With 148.5g filmogen, 1.5g titanium dioxide and 2000mL distilled water mix homogeneously; Stirred 90 minutes; In fluid bed, carry out coating under 70 ℃ as coating solution, can prepare 1000 in methyl salicylate lactoside tablet, every contains active component methyl salicylate lactoside 500mg.
The methyl salicylate lactoside tablet of application implementation example 1～5 preparation is investigated its outward appearance, friability, hardness, disintegration and dissolution, and is as shown in table 1.
The methyl salicylate lactoside tablet of application implementation example 2 preparations; With reference to " Chinese pharmacopoeia version appendix in 2010 Chinese medicine study on the stability guideline requirement; Influence factor and long-term accelerated test research have been carried out; Investigate according to indexs such as related substance, content, dissolution in the quality standard, shown in table 2, table 3.
Table 1
Table 2
Table 3
* percentage ratio all is weight percentage in the table.
The result of table 1 shows, and is fast according to the methyl salicylate lactoside disintegration of tablet speed of the inventive method preparation, dissolution is high and have certain rigidity, and is not easily broken.
The result of table 2, table 3 shows, according to the methyl salicylate lactoside tablet of the inventive method preparation in influence factors such as high temperature, high humidity and strong illumination test with quicken all had fabulous stability in the process in six months for a long time.
The foregoing description just illustrates of the present invention, and the present invention also can implement with other ad hoc fashion or other particular form, and does not depart from main idea of the present invention or substitutive characteristics.Therefore, the embodiment of description all should be regarded as illustrative from any aspect but not be determinate.Scope of the present invention should be by additional claim explanation, and any intention and equivalent variation of scope with claim also should be within the scope of the present invention.
Claims (10)
1. pharmaceutical composition that contains the methyl salicylate lactoside, this pharmaceutical composition comprises the raw material of following weight portion: 0.5～6 part of 100 parts of methyl salicylate lactosides, 20～300 parts of diluent, 1～8 part of disintegrating agent, 20～400 parts of binding agents and lubricant.
2. the pharmaceutical composition that contains the methyl salicylate lactoside according to claim 1 is characterized in that said diluent is selected from one or more in starch, cyclodextrin, microcrystalline Cellulose and the lactose; Said disintegrating agent is carboxymethyl starch sodium, polyvinylpolypyrrolidone or the mixture of the two; Said binding agent is selected from starch slurry, polyvinylpyrrolidone K
30In alcoholic solution, dehydrated alcohol and the water one or more; Said lubricant is selected from one or more in magnesium stearate, Pulvis Talci and the stearic acid.
3. a methyl salicylate lactoside tablet reaches the film-coat that evenly is coated on the sheet wicking surface by label and forms;
Said label comprises the raw material of following weight portion: 0.5～6 part of 100 parts of methyl salicylate lactosides, 20～300 parts of diluent, 1～8 part of disintegrating agent, 20～400 parts of binding agents and lubricant;
Said film-coat comprises the raw material of following weight portion: 20～200 parts of filmogens, 600～2000 parts of 0～50 part of coalescents and solvents.
4. a kind of methyl salicylate lactoside tablet according to claim 3 is characterized in that said diluent is selected from one or more in starch, cyclodextrin, microcrystalline Cellulose and the lactose; Said disintegrating agent is carboxymethyl starch sodium, polyvinylpolypyrrolidone or the mixture of the two; Said binding agent is selected from starch slurry, polyvinylpyrrolidone K
30In alcoholic solution, dehydrated alcohol and the water one or more; Said lubricant is selected from one or more in magnesium stearate, Pulvis Talci and the stearic acid.
5. a kind of methyl salicylate lactoside tablet according to claim 3 is characterized in that said filmogen is selected from one or more in hypromellose, ethyl cellulose, glyceryl triacetate, polyacrylic acid resin, the polyvinyl alcohol; Said coalescents is selected from one or more in titanium dioxide, Pulvis Talci or the Polyethylene Glycol, and said solvent is the solution that water and dehydrated alcohol mix with any ratio.
6. a kind of methyl salicylate lactoside tablet according to claim 5 is characterized in that said filmogen comprises hypromellose 0～100 weight portion, ethyl cellulose 0～40 weight portion and glyceryl triacetate 0～40 weight portion; Said coalescents comprises titanium dioxide 0～10 weight portion, Pulvis Talci 0～20 weight portion and Polyethylene Glycol 0～20 weight portion; Said solvent is that concentration of volume percent is 70～95% alcoholic solution 700～1800 weight portions.
7. a kind of methyl salicylate lactoside tablet according to claim 6; It is characterized in that; Said filmogen comprises hypromellose 1～100 weight portion, ethyl cellulose 0.5～20 weight portion and glyceryl triacetate 0.1～20 weight portion, and said coalescents is titanium dioxide 0～5 weight portion.
8. the method for preparing of the described a kind of methyl salicylate lactoside tablet of claim 3 comprises the steps:
(1) diluent and the disintegrating agent of said weight portion are crossed 10～100 mesh sieves, get the tablet inserts;
(2) the methyl salicylate lactoside of said weight portion is crossed 10～100 mesh sieves, get compound with the tablet inserts mix homogeneously of step (1);
(3) the binding agent wet granulation of the said weight portion of adding in compound; With 10～60 mesh sieve granulate, drying is 1～6 hour under 30～80 ℃ condition, and degree of drying is for controlling pellet moisture between 1～5%;
(4) lubricant of the said weight portion of adding in dried granulate, mix homogeneously is put the compacting label that gets in blocks on the tablet machine.
(5) filmogen, coalescents and the solvent with weight portion described in the film-coat is mixed with emulsion, stirs 30～90 minutes, obtains coating solution;
(6) under 30～70 ℃ condition, label being carried out coating, is standard to increase 1%～5% of label weight portion, obtains containing the tablet of methyl salicylate lactoside.
9. the method for preparing of a kind of methyl salicylate lactoside tablet according to claim 8 is characterized in that, in the step (3), baking temperature is 40～60 ℃, and be 2～4 hours drying time.
10. the method for preparing of a kind of methyl salicylate lactoside tablet according to claim 8 is characterized in that, in the step (4), in fluid bed or coating pan, label is carried out coating, and the coating temperature is 40～60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110410629.XA CN102526080B (en) | 2011-12-12 | 2011-12-12 | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110410629.XA CN102526080B (en) | 2011-12-12 | 2011-12-12 | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526080A true CN102526080A (en) | 2012-07-04 |
| CN102526080B CN102526080B (en) | 2014-07-30 |
Family
ID=46334903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110410629.XA Active CN102526080B (en) | 2011-12-12 | 2011-12-12 | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526080B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103005431A (en) * | 2012-12-03 | 2013-04-03 | 上海交通大学 | Seedless roxburgh rose-angelica keiskei composite chewable tablet and preparation method thereof |
| CN106924272A (en) * | 2015-12-31 | 2017-07-07 | 中国医学科学院药物研究所 | Purposes of the salicylic acid glucosides methyl in prevention and/or systemic lupus erythematosus and its complication medicine is prepared |
| CN108239126A (en) * | 2016-12-26 | 2018-07-03 | 中国医学科学院药物研究所 | Gaultherolin lactoside III type solid matter of crystalline substance and preparation method and its composition and purposes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863934A (en) * | 2009-04-20 | 2010-10-20 | 中国医学科学院药物研究所 | Salicylic acid glucosides methyl compound, and synthesis method and purposes thereof |
-
2011
- 2011-12-12 CN CN201110410629.XA patent/CN102526080B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863934A (en) * | 2009-04-20 | 2010-10-20 | 中国医学科学院药物研究所 | Salicylic acid glucosides methyl compound, and synthesis method and purposes thereof |
Non-Patent Citations (1)
| Title |
|---|
| XI LAN等: "Methyl salicylate 2-O-b-D-lactoside, a novel salicylic acid analogue, acts as an anti-inflammatory agent on microglia and astrocytes", 《JOURNAL OF NEUROINFLAMMATION》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103005431A (en) * | 2012-12-03 | 2013-04-03 | 上海交通大学 | Seedless roxburgh rose-angelica keiskei composite chewable tablet and preparation method thereof |
| CN103005431B (en) * | 2012-12-03 | 2014-02-19 | 上海交通大学 | Seedless roxburgh rose-angelica keiskei composite chewable tablet and preparation method thereof |
| CN106924272A (en) * | 2015-12-31 | 2017-07-07 | 中国医学科学院药物研究所 | Purposes of the salicylic acid glucosides methyl in prevention and/or systemic lupus erythematosus and its complication medicine is prepared |
| CN106924272B (en) * | 2015-12-31 | 2021-04-13 | 中国医学科学院药物研究所 | Application of methyl salicylate glucoside in preparation of medicines for preventing and/or treating systemic lupus erythematosus and complications thereof |
| CN108239126A (en) * | 2016-12-26 | 2018-07-03 | 中国医学科学院药物研究所 | Gaultherolin lactoside III type solid matter of crystalline substance and preparation method and its composition and purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526080B (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104958282A (en) | Tapentadol compositions | |
| CN104906064A (en) | Pregabalin intragastric floating sustained release tablet and preparation method thereof | |
| CN108451916B (en) | Acetaminophen pharmaceutical composition preparation and preparation method thereof | |
| RU2008151946A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE LONG-TERM RELEASE OF Phenylephrine | |
| JP2017531637A (en) | Pregabalin sustained-release preparation | |
| CN105412038A (en) | Compound preparation containing vonoprazan and non-steroidal anti-inflammatory drugs | |
| CN102526080B (en) | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof | |
| AU2014349782B2 (en) | Slow-release solid oral compositions | |
| JP5208729B2 (en) | Method for producing sustained-release tablets | |
| WO2008083561A1 (en) | Oral pharmaceutical composition of glycyrrhizin or its salts and the preparation method thereof | |
| CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
| JP2015091830A (en) | Galenical formulations of organic compounds | |
| KR101559339B1 (en) | Fast-release tablet comprising high amounts of herbal substances | |
| EP2793853B1 (en) | Pharmaceutical formulations of flurbiprofen and glucosamin | |
| CN103083314A (en) | Compound ibuprofen having gastrointestinal protective effect | |
| EP2809305B1 (en) | Bilayer tablet formulations of flurbiprofen and glucosamin | |
| CN103816131B (en) | Flurbiprofen double-layer osmotic pump controlled-release tablet and preparation method thereof | |
| CN102552206B (en) | Medicinal composition with anti-inflammatory and analgesic effects | |
| JP2001139469A (en) | Novel sustained release preparation composite | |
| KR20150044670A (en) | Controlled-release pharmaceutical composition of propionic acid derivatives | |
| TR201802898T4 (en) | Combined immediate release formulations of flurbiprofen and famotidine. | |
| CN101530406A (en) | Compound enteric-coated preparation and preparation method thereof | |
| CN101502504A (en) | Nimesulide enteric-coated formulation composition and method for preparing the same | |
| JP2009191035A (en) | Limited-time release preparation | |
| RU2521231C2 (en) | Glucosamine prolonged release dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: PHARMACOLOGY INST. OF CAMS Free format text: FORMER OWNER: BEIJING UNION PHARMACEUTICAL FACTORY Effective date: 20130128 Free format text: FORMER OWNER: PHARMACOLOGY INST. OF CAMS Effective date: 20130128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 102600 DAXING, BEIJING TO: 100050 XICHENG, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130128 Address after: 100050 Beijing city Xicheng District Xiannongtan Street No. 1 Applicant after: Institute of Materia Medica of Chinese Academy of Medical Sciences Address before: 102600, Daxing District, Beijing Huang Town, Xingye Road, Beijing Concord pharmaceutical factory Applicant before: Beijing Union Pharmaceutical Factory Applicant before: Institute of Materia Medica of Chinese Academy of Medical Sciences |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |